Federal Policy, DEA Rescheduling & Healthcare Economics
Federal Policy, DEA Rescheduling & Healthcare Economics
Expert clinical testimony before Congress and national news analysis: examining Schedule III reclassification, independent university trials under the Medical Marijuana Research Act, and the clinical case for health insurance parity.
Massachusetts 60-Day Rolling Supply Limit: Patient Protections
Under Massachusetts Cannabis Control Commission (CCC) regulations, certified medical patients have legal authorization to purchase and possess up to a 60-day rolling supply (up to 10 ounces of cannabis or its equivalent in concentrates/infused products). Read Dr. Caplan’s definitive clinical breakdown of supply thresholds, hardship dispensations, and how certified patients are protected under state statutes.
Read Full Massachusetts 60-Day Supply Guide ↗
The 4 Core Battles in Federal Cannabis Reform
Key clinical and regulatory priorities presented in Dr. Caplan’s administrative hearings and congressional testimony.
🏛️ Schedule III vs. Real Patient Access
Moving cannabis from Schedule I to Schedule III acknowledges its accepted medical use under federal law and eliminates IRS 280E taxation. However, Schedule III requires FDA-approved NDA/IND manufacturing pipelines—which would outlaw existing state-regulated dispensaries unless safe harbors protect state patient access.
🛡️ Physician Recommendation Safe Harbors
Under federal Schedule III rules, standard prescription requirements apply. Since botanical chemovars cannot be prescribed via typical pharmacy scripts, Dr. Caplan advocates for clear federal recognition of physician certifications modeled after Conant v. Walters.
📊 Dismantling the Research Monopoly
For decades, the NIDA Mississippi monopoly restricted studies to sub-par, desiccated plant material. With the Medical Marijuana Research Act, independent academic universities can finally study the exact chemovars, terpenes, and extraction formats that patients consume.
💰 Health Insurance & Payer Parity
Over 20% of chronic pain patients substitute cannabis for prescription opioids. When insurers refuse to cover clinician consultations or botanical medications, low-income patients are forced back onto addictive pharmaceuticals that carry 100% insurance coverage.
Mass Medical Marijuana Online Registration: Step-by-Step Portal Walkthrough
Looking to certify or renew your patient status with the Massachusetts Cannabis Control Commission? CĒD Clinic has compiled the complete step-by-step walkthrough covering physician PINs, residency verification, government identification, and same-day digital temporary card issuance.
Explore Clinical & Media Investigations
🎓 Doctor-to-Doctor Grand Rounds
Harvard medical keynotes, pharmacology lectures, and physician-to-physician education on CYP450 metabolism and endocannabinoid science.
🌍 Voice of America International Feature
Documentary profiling CĒD Clinic’s clinical care blueprint broadcast to 300M+ viewers in dozens of languages worldwide.
💊 Opioid-Sparing & Harm Reduction
7News WHDH investigation into substituting botanical cannabis for lethal prescription narcotics and benzodiazepines.
⭐ Montel Williams 3-Part Masterclass
Montel Williams & Dr. Caplan on navigating Multiple Sclerosis, chronic illness, and evidence-based dosing protocols.
Whether you are seeking state-certified medical card protection in Massachusetts or individualized guidance for chronic pain, oncology recovery, or neurological disorders, CĒD Clinic provides comprehensive physician care.
